Brompheniramine is a halogenated antihistamine derivative of pheniramine that exhibits anticholinergic and neuromodulatory activities. Brompheniramine inhibits the H1 histamine receptor and also displays non-selective inhibition of muscarinic acetylcholine receptors (mAChRs). Brompheniramine inhibits histamine-induced vasodilation and also potentiates the effects of opioid analgesics. Additionally, brompheniramine is the parent compound of zimelidine, a selective serotonin reuptake inhibitor (SSRI) that exhibits antidepressant activity; zimelidine inhibits pre-synaptic 5-HT reuptake and may inhibit the serotonin transporter (SERT) or monoamine oxidase B (MAO-B).